BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 24, 2004
View Archived Issues
Kosan Stops NSCLC Phase II But Upbeat' On Epothilones
Read More
DOV's Anti-Anxiety Drug Entering Pivotal Phase III
Read More
Other News To Note
Read More
Cubist Raises More Than $104M In Public Offering
Cubist Pharmaceuticals Inc. raised more than $100 million through a larger public offering of its common shares than originally expected. (BioWorld Today)
Read More
Medarex Partnering Lupus Antibodies With MedImmune
Read More